Fig. 5From: Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapyComparison of DFS(g) and OS(h) curves between patients with different groups (irAEs, No-irAEs). g: Patients with irAEs had longer DFS [HR 1.872 (95% CI, 0.627, 2.275); p = 0.020]; f: Patients with irAEs had longer OS [HR 2.548(95% CI, 0.935, 2.415); p = 0.013]Back to article page